Ovid Therapeutics

Conquering brain conditions with courageous science.
Our guidelines:

[Ovid Therapeutics @OvidRx]

We’re pleased to share that Ovid Therapeutics has entered a definitive agreement with Immedica Pharma AB for the sale of our future ganaxolone royalty rights outside China.

The deal provides non-dilutive capital to support our core pipeline.

Read more: https://t.co/YUaCeyzwrR

[Ovid Therapeutics @OvidRx]

Ovid CEO Jeremy Levin will moderate “Supporting Research at the Intersection of Policy and Science” at #MITCEO later today.

He’ll lead a timely discussion with Congressman Jake Auchincloss, former FDA Commissioner Dr. Robert Califf, and MIT President Emerita Dr. Susan Hockfield.

@LongwoodLeaders @LongwoodFund

[Ovid Therapeutics @OvidRx]

Thank you to everyone who joined us for Biomarkers in Epilepsy.

Biomarkers are changing how we approach anti-seizure drug development - offering earlier insights and helping reduce risk.

Dr. Alex Rotenberg joined us to share how this applies to OV329.

Watch the replay: https://t.co/fNFw9IG7eL

[Ovid Therapeutics @OvidRx]

We’re proud to celebrate Meg Alexander, Ovid’s President & COO, as one of @InVivo_Citeline’s 2025 Rising Leaders.

She reflects on bold decisions, team-driven leadership, and the future of innovation in neurology.

Read the interview: https://t.co/WOOmJVjLEt

[Ovid Therapeutics @OvidRx]

Join Ovid leadership and Dr. Alexander Rotenberg at 9:30 AM ET today for a conversation on how biomarkers are shaping the future of epilepsy research and anti-seizure drug development - featuring OV329, our next-gen GABA-AT inhibitor.

Watch here: https://t.co/9hfRcHpJpW

[Ovid Therapeutics @OvidRx]

Ovid Therapeutics will host Biomarkers in Epilepsy, an investor and media event, on June 12 from 9:30–10:30 AM ET. The event will highlight the role of biomarkers in epilepsy research, with a focus on OV329 and insights from Dr. Alexander Rotenberg.

Register here: https://t.co/SD9W6xfsOK
Full release: https://t.co/ppah5F27t8

[Ovid Therapeutics @OvidRx]

Today, we announced our Q1 2025 results and business updates. In a pivotal year, we are focused on key milestones, including data readouts for OV329 and OV350, and advancing small molecule therapies to restore neural balance in serious neurological conditions.

Learn more: https://t.co/NxsXUm8onR

[Ovid Therapeutics @OvidRx]

We’re excited to announce that Ovid President & COO, Meg Alexander will be presenting at the 24th Annual Needham Virtual Healthcare Conference on April 7th.

Read the full announcement, including details for accessing the webcast, here: https://t.co/GldZFhv0vy

[Ovid Therapeutics @OvidRx]

Today, we shared our Q4 2024 results, highlighting key business developments and a major milestone with OV350, now in a first-in-human study—furthering our commitment to addressing the neurological symptoms that matter most to patients.

Learn more: https://t.co/E8MbTs4shy

[Ovid Therapeutics @OvidRx]

Pleased to welcome Dr. Stelios Papadopoulos to our Board of Directors! His leadership & strategic insights will be invaluable as Ovid continues its mission to develop transformative medicines for brain conditions with significant unmet need.

Learn more: https://t.co/FHtQdpJ9bj

[Ovid Therapeutics @OvidRx]

Our President and COO Meg Alexander will be presenting at the TD Cowen 45th Annual Health Care Conference.

Read the full announcement, including details for accessing the webcast: https://t.co/VHJqUcPoeC

[Ovid Therapeutics @OvidRx]

Small molecules have the potential to make a big impact on CNS. As @jmaxlevin explains, they target specific receptors, offering potentially effective therapies with fewer side effects. At Ovid, we’re advancing assets like OV350, which activate KCC2 to restore brain balance.

[Ovid Therapeutics @OvidRx]

Ovid’s President and COO, Meg Alexander, was recently featured in the final part of @PharmaScrip's “Scrip Asks… What Does 2025 Hold For Biopharma?”

Read Meg’s full quote on the advancements in neurotherapeutics in the article by @ScripEleanor here: https://t.co/zyAdou5TGP

[Ovid Therapeutics @OvidRx]

By targeting hyperexcitability, directly activating KCC2 could unlock new therapeutic possibilities. Listen to Dr. Noebels explain why this precision approach is key. ​

#KCC2

[Ovid Therapeutics @OvidRx]

Congrats to Dr. Richard Silverman and team on their study of OV329 in @PNASNews ! This investigational GABA-AT inhibitor shows promise at dampening neuronal excitability and offering therapeutic benefit beyond epilepsy.

Learn more: https://t.co/b4fRgB673v

[PNASNews @PNASNews]

The investigational analgesic drug OV329, which inhibits GABA aminotransferase, provides pain relief in rodent models as effectively as morphine in some cases—but without causing addiction or tolerance. In PNAS: https://t.co/tblYsIBm5L